Skip to Main Content

Paper Details

A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Clin Cancer Res
3
2023
AKT, ALDH1A1, ALDH1A1+, ALDH1A1+ cells, Drug-resistant ALDH1A1+/pAKT+ subclones, glioblastoma, pAKT, patient, patient cells, rare ALDH1A1+ tumor cells, subclones, temozolomide, tumor, tumor cells, vital, vital cell samples
Author NameAffiliation
Andreas TillInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn
Holger Fr??hlichBonn-Aachen International Center for IT (B-IT), University of Bonn
Holger Fr??hlich
Marc Remke
Marc RemkeUniversity Hospital Dusseldorf
Christel Herold-MendeUniversity of Heidelberg
Torsten PietschInstitute of Neuropathology, University of Bonn
Guido Reifenberger
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University
Michael WellerUniversity Hospital and University of Zurich
Martin GlasUniversity Hospital Essen
Martin Glas
Martin GlasDivision of Clinical Neurooncology, University Hospital Essen
Martin GlasWest German Cancer Center (WTZ), University Hospital Essen
Bj??rn SchefflerUniversity Hospital Essen
Bj??rn Scheffler
Bj??rn SchefflerWest German Cancer Center (WTZ), University Hospital Essen
Bj??rn SchefflerGerman Cancer Research Center (DKFZ)
Bj??rn SchefflerUniversity Duisburg-Essen
  • 1 - 19

Datasets

Release 1.2